Personalized medicine

Research to personalize treatments.

Together, let’s overcome cancer.

The “personalized medicine in oncology” research axis aims to develop clinical applications of molecular biology and cancer immunotherapy for better individualization of oncological therapies. Medical oncology clinicians, researchers and lecturers from INSERM Unit UMR 1231, anatomical pathologists, biologists and oncogeneticists are working on these subjects using a cancer biology transfer platform. This axis gives rise, on the clinical side, to therapeutic trials; on the research side, to work in molecular biology and immunotherapy.

This research activity is structured into 3 themes:

1

“Using basic research in immunology to implement transfer and clinical research”

This theme develops fundamental research in the field of cancer immunotherapy.

2

“Development of molecular analyses in oncology”

This theme aims to develop high-throughput sequencing techniques to characterize patients’ tumors and offer them targeted therapies or access to early clinical studies. It is composed of three programs.

3

“Early research to personalize treatments”

This theme, led by the CGFL Early Phase Unit, labeled CLIP2 (Early Phase Cancer Center) since 2010. The objectives are multiple. Continue and strengthen the conduct and analysis of phase I and II studies, develop new early phase studies and new immunological therapeutic strategies through internal promotion with 3 programs:

Development of new immunological therapeutic strategies
Development of phase studies
Development of new techniques for early diagnosis of cancer and personalized monitoring of patients

Vous souhaitez financer un projet de recherche au CGFL ?

Rendez-vous sur notre plateforme
et découvrez nos projets en cours